{"id":32988,"date":"2025-09-08T20:01:00","date_gmt":"2025-09-08T20:01:00","guid":{"rendered":"https:\/\/www.hotelsalepage.com\/feed\/cision-pr-newswire\/sirtex-receives-expanded-ce-mark-approval-for-sir-spheres-y-90-resin-microspheres\/"},"modified":"2025-09-08T20:01:00","modified_gmt":"2025-09-08T20:01:00","slug":"sirtex-receives-expanded-ce-mark-approval-for-sir-spheres-y-90-resin-microspheres","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=32988","title":{"rendered":"Sirtex Receives Expanded CE Mark Approval for SIR-Spheres\u00ae Y-90 Resin Microspheres"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Broadened indication increases access to liver cancer treatment across Europe<\/span> and CE-marked territories.<\/i><\/p>\n

WOBURN, Mass.<\/span><\/span>, Sept. 8, 2025<\/span><\/span> \/PRNewswire\/ — Sirtex Medical (“Sirtex”)<\/a>, a leading manufacturer of minimally invasive interventional oncology solutions, today announced that it has received an expanded CE Mark approval for SIR-Spheres\u00ae Y-90<\/span> resin microspheres for the treatment of patients with liver cancer. With this expansion, eligibility now covers both primary and secondary liver metastases, increasing patient access to a well-established, targeted therapy.<\/p>\n

“This milestone is about more than regulatory approval\u2014it’s about giving hope and options back to patients facing some of the toughest cancer diagnoses,” said Matt Schmidt<\/span>, CEO of Sirtex Medical. “By expanding access to SIR-Spheres\u00ae, we’re ensuring that more people can benefit from a well-tolerated therapy when they need it most.”<\/p>\n

Radioembolization\u2014also known as selective internal radiation therapy (SIRT)\u2014delivers yttrium-90 directly to tumors via the hepatic artery, allowing for high-dose, targeted radiation aiming to minimize impact to surrounding healthy tissue.<\/p>\n

“Y-90<\/span> radioembolization has long demonstrated clinical value in managing complex liver tumors,” said Prof. Dr. med. Jens Ricke<\/span>, Director of the Clinic and Polyclinic of Radiology at the University Hospital Ludwig-Maximilians in Munich<\/span>, Germany.\u00a0“With this expanded CE Mark, more patients will have access to a therapy that can extend life, improve quality of life, and offer hope when other treatments may no longer be effective.”<\/p>\n

The CE Mark expansion follows an extensive review of clinical data demonstrating the safety and effectiveness of SIR-Spheres\u00ae across diverse liver metastases. Together with the FDA’s recent approval of SIR-Spheres\u00ae Y-90<\/span> resin microspheres for the treatment of unresectable HCC in the United States<\/span>, this milestone underscores the growing global recognition of SIR-Spheres\u00ae as a versatile, differentiated therapy and reinforces the Sirtex commitment to advancing liver-directed interventional oncology.<\/p>\n

For more information and details on how to incorporate SIR-Spheres\u00ae into your practice, please contact Sirtex at\u00a0info-use@sirtex.com<\/b><\/a>.<\/p>\n

About SIR-Spheres<\/b>\u00ae in Europe<\/span>
<\/b>SIR-Spheres\u00ae Y-90<\/span> resin microspheres are indicated for the treatment of:<\/p>\n